Dergiler / Şişli Etfal Hastanesi Tıp Bülteni / 2019 / Cilt: 53 - Sayı: 2

Clinicopathologic Differences Between Micropapillary and Papillary Thyroid Carcinoma

Sayfa
120–124
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Thus, thepatients having these histopathological features of the tumor should be followed more carefully.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: The aim of this study is observing the clinicopathologic features of thyroid papillary microcarcinomas (PTMs) andcomparing these features with papillary thyroid carcinoma (PTC).Methods: A total of 86 surgically treated patients suffering from PTC were evaluated retrospectively.
📊
Temel Bulgular & Veri:Group 1 (G1) included patients with a tumor 1 cm.
💡
Sonuç & Katkı:Thus, thepatients having these histopathological features of the tumor should be followed more carefully.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: The aim of this study is observing the clinicopathologic features of thyroid papillary microcarcinomas (PTMs) andcomparing these features with papillary thyroid carcinoma (PTC).Methods: A total of 86 surgically treated patients suffering from PTC were evaluated retrospectively. Group 1 (G1) included patients with a tumor 1 cm. The two groups were compared in termsof the preoperative thyroid-stimulating hormone (TSH) level, anti-thyroid peroxidase antibody (anti-TPO) and antithyroglobulinantibody (TgAb) values, multicentricity, the lymphovascular invasion rate, the presence of extrathyroidal extension, and centraland/or lateral lymph node metastasis.Results: There was no statistically significant difference observed between the groups in terms of the preoperative TSH level,anti-TPO, and TgAb values. The rate of multicentricity of the tumor in G2 was 66%, while it was 36% in G1 (p<0.001). The lymphovascular invasion rate in G1 was 14.2%, while it was 61% in G2 (p<0.001). The extrathyroidal extension rate of the tumor cells in G1was 21.4%, while it was 63.6% in G2 (p<0.001). The central lymph node metastasis rate in G2 was 38.6%, while it was 4.8% in G1(p<0.001). The lateral lymph node metastasis rate in G2 was 20.5%, while it was 0% in G1 (p<0.001).Conclusion: PTMs are generally associated with good prognostic factors with high survival rates. However, the risk factors such asmultifocality, extrathyroidal extension, and lymphovascular invasion increasing the recurrence risk are not rare in PTM. Thus, thepatients having these histopathological features of the tumor should be followed more carefully.

🔖

Bu Makaleye Atıf Yap

KARTAL, K., AYGÜN, N., ULUDAĞ, M. (2019). Clinicopathologic Differences Between Micropapillary and Papillary Thyroid Carcinoma. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 53 - Sayı: 2, 120–124. https://ajindex.com/articles/363440

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140:317–22
  2. Davies L, Morris LG, Haymart M, Chen AY, Goldenberg D, Morris J, et al; AACE Endocrine Surgery Scientific Committee. American Association Of Clinical Endocrinologists And American College Of Endocrinology Disease State Clinical Review: The Increasing Incidence Of Thyroid Cancer. Endocr Pract 2015;21:686–96
  3. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003;13:381–7
  4. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 1992;112:1139–46
  5. Braga M, Graf H, Ogata A, Batista J, Hakim NC. Aggressive behavior of papillary microcarcinoma in a patient with Graves' disease initially presenting as cystic neck mass. J Endocrinol Invest 2002;25:250–3
  6. Pelizzo MR, Boschin IM, Toniato A, Pagetta C, Piotto A, Bernante P, et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12- year experience. Nucl Med Commun 2004;25:547–52
  7. Chow SM, Law SC, Au SK, Mang O, Yau S, Yuen KT, et al. Changes in clinical presentation, management and outcome in 1348 patients with differentiated thyroid carcinoma: experience in a single institute in Hong Kong, 1960-2000. Clin Oncol (R Coll Radiol) 2003;15:329–36
  8. Yu XM, Wan Y, Sippel RS, Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 2011;254:653–60
  9. Aygün N, İşgör A, Uludağ M. Can Active Surveillance be an Alternative to Surgery in Papillary Thyroid Microcar- cinoma?: The Current Situation Worldwide. Med Bull Sisli Etfal Hosp 2018;52:233–43
  10. Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008;144:980–7
  11. Noguchi S, Yamashita H, Uchino S, Watanabe S. Papillary microcarcinoma. World J Surg 2008;32:747–53
  12. Kim SK, Park I, Woo JW, Lee JH, Choe JH, Kim JH, et al. Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: Analysis of 8,676 patients at a single institution. Surgery 2017;161:485–92
  13. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS,